Americord makes breakthrough in treating Motor Neuron Disease with cord blood stem cells

Americord, a cutting-edge private stem cell bank, has announced the successful transfer of cord blood stem cells to a patient in India to treat motor neuron disease. This progressive neurological disease, still in search of effective treatments, could soon see FDA-approved options thanks to the promising results of stem cells.

In collaboration with Indian healthcare professionals, Americord has overcome regulatory challenges to facilitate this transfer. India, with its increasing investments in biotechnology, has proven to be a strategic partner. This operation not only highlights the effectiveness of cord blood preservation but also its versatility, as the stem cells have been used for a distant family member, in this case the grandmother, thanks to strategic management of preserved resources.

Martin Smithmyer, Co-CEO and founder of Americord, emphasized the importance of this milestone in using stem cells for innovative treatments. With over 80 treatable conditions by these cells to date, cord blood banking is positioning itself as a future solution for families.